ResearcherNational Institute of Biomedical Innovation, Health and NutritionNo recent work listed

Takahiko Nishigaki

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5072947544. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 6

Papers, trials and grants by year

2020: 1 paper

Papers 1

Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer. Co-author DOI 10.1038/s41416-020-0781-2 ↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Shigehiro Tsujii · 1 shared paper, 2020 · strength 0.08
- Paper Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer. DOI 10.1038/s41416-020-0781-2 ↗
Masaki Mori · 1 shared paper, 2020 · strength 0.08
- Paper Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer. DOI 10.1038/s41416-020-0781-2 ↗
Yuichiro Doki · 1 shared paper, 2020 · strength 0.08
- Paper Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer. DOI 10.1038/s41416-020-0781-2 ↗
Toru Otsuru · 1 shared paper, 2020 · strength 0.08
- Paper Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer. DOI 10.1038/s41416-020-0781-2 ↗
Tetsuji Naka · 1 shared paper, 2020 · strength 0.08
- Paper Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer. DOI 10.1038/s41416-020-0781-2 ↗
Hidetoshi Eguchi · 1 shared paper, 2020 · strength 0.08
- Paper Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer. DOI 10.1038/s41416-020-0781-2 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.